BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3733
-0.0193 (-4.92%)
At close: Mar 28, 2025, 4:00 PM
0.3695
-0.0038 (-1.03%)
After-hours: Mar 28, 2025, 7:56 PM EDT
BioAtla Employees
BioAtla had 65 employees as of December 31, 2023. The number of employees decreased by 1 or -1.52% compared to the previous year.
Employees
65
Change (1Y)
-1
Growth (1Y)
-1.52%
Revenue / Employee
$169,231
Profits / Employee
-$1,073,477
Market Cap
21.66M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65 | -1 | -1.52% |
Dec 31, 2022 | 66 | 10 | 17.86% |
Dec 31, 2021 | 56 | 20 | 55.56% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BCAB News
- 3 days ago - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - BioAtla Cuts 30% of Jobs in Restructuring Effort - Market Watch
- 3 days ago - BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 10 days ago - BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - GlobeNewsWire
- 11 days ago - BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - GlobeNewsWire
- 26 days ago - AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology) - GlobeNewsWire
- 3 months ago - BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - GlobeNewsWire
- 3 months ago - BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - GlobeNewsWire